171 related articles for article (PubMed ID: 8054507)
1. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
2. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases.
Dezso B; Haas GP; Hamzavi F; Kim S; Montecillo EJ; Benson PD; Pontes JE; Maughan RL; Hillman GG
Clin Cancer Res; 1996 Sep; 2(9):1543-52. PubMed ID: 9816331
[TBL] [Abstract][Full Text] [Related]
4. Influence of tumor site on the therapy of murine kidney cancer.
Chakrabarty A; Hillman GG; Maughan RL; Visscher DW; Ali E; Pontes JE; Haas GP
Anticancer Res; 1994; 14(2A):373-8. PubMed ID: 8017836
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
6. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice.
Rocha FG; Chaves KC; Chammas R; Peron JP; Rizzo LV; Schor N; Bellini MH
Cancer Immunol Immunother; 2010 Sep; 59(9):1357-65. PubMed ID: 20490489
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
Huland E; Heinzer H; Huland H
Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
[TBL] [Abstract][Full Text] [Related]
9. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma.
Dybal EJ; Haas GP; Maughan RL; Sud S; Pontes JE; Hillman GG
J Urol; 1992 Oct; 148(4):1331-7. PubMed ID: 1404669
[TBL] [Abstract][Full Text] [Related]
10. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
Salup RR; Wiltrout RH
Cancer Res; 1986 Jul; 46(7):3358-63. PubMed ID: 3486710
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines.
Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP
J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
16. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma.
Hillman GG; Slos P; Wang Y; Wright JL; Layer A; De Meyer M; Yudelev M; Che M; Forman JD
Cancer Gene Ther; 2004 Jan; 11(1):61-72. PubMed ID: 14681727
[TBL] [Abstract][Full Text] [Related]
17. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
Huland E; Heinzer H; Huland H
Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219
[TBL] [Abstract][Full Text] [Related]
18. Neutron or photon irradiation for prostate tumors: enhancement of cytokine therapy in a metastatic tumor model.
Hillman GG; Maughan RL; Grignon DJ; Yudelev M; Rubio J; Tekyi-Mensah S; Layer A; Che M; Forman JD
Clin Cancer Res; 2001 Jan; 7(1):136-44. PubMed ID: 11205901
[TBL] [Abstract][Full Text] [Related]
19. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
Yockman JW; Kim WJ; Chang CW; Kim SW
Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245
[TBL] [Abstract][Full Text] [Related]
20. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
